EPITHELIAL OVARIAN CANCER
Clinical trials for EPITHELIAL OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new EPITHELIAL OVARIAN CANCER trials appear
Sign up with your email to follow new studies for EPITHELIAL OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Early cancer drug trial halted after just 3 patients
Disease control TerminatedThis early-stage study tested a new drug called AMG 794 in adults with advanced lung, ovarian, or other solid tumors that have a specific protein (claudin 6). The main goal was to check safety and find the right dose. The trial was stopped early after enrolling only 3 participant…
Matched conditions: EPITHELIAL OVARIAN CANCER
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated May 26, 2026 06:48 UTC
-
New hope for tough ovarian cancer? trial tests targeted drug vs standard chemo
Disease control TerminatedThis study tested a new drug called luveltamab tazevibulin against standard chemotherapy in about 600 women whose ovarian cancer had stopped responding to platinum-based treatment. The drug targets a protein (FOLR1) found on many ovarian cancer cells. The trial was terminated ear…
Matched conditions: EPITHELIAL OVARIAN CANCER
Phase: PHASE2, PHASE3 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Personalized immune cell therapy targets Hard-to-Treat cancers
Disease control TerminatedThis early-phase study tested a new treatment called ITIL-306 for people with advanced ovarian, lung, or kidney cancers that stopped responding to standard therapies. ITIL-306 uses a patient's own immune cells, modified to better recognize and attack tumors. The study was termina…
Matched conditions: EPITHELIAL OVARIAN CANCER
Phase: PHASE1 • Sponsor: Instil Bio • Aim: Disease control
Last updated May 18, 2026 12:03 UTC